AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 231 min read$HIMS

Okupe Oluyemi sold $619K of HIMS

Okupe Oluyemi (Chief Financial Officer) sold 18,197 shares of Hims & Hers Health, Inc. (HIMS) at $34.03 ($0.62M total) on 2026-06-22 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Okupe Oluyemi
Published Jun 23, 2026, 10:39 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 23, 2026, 10:40 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$HIMS
Neutral
medium confidence
Mentioned
$HIMS
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HIMSNeutralLow
01

Why it matters

Confirms a CFO open-market sale executed under a pre-arranged 10b5-1 plan; no new fundamentals are provided.

02

Market read

Traders may note the insider sale for sentiment, but it is unlikely to drive price without additional company-specific catalysts.

03

What to watch

The filing does not indicate why shares were sold or whether other insiders bought; without additional context, the trade is best treated as routine planned selling.

Relevance 4/10Novelty 4/10Timing: Form 4 filed 2026-06-23 (sale dated 2026-06-22)

Background

The article is an SEC Form 4 insider transaction disclosure for Hims & Hers Health, Inc.

Company-level read

Ticker impact

$HIMSNeutralMedium confidence
Context

HIMS CFO Okupe Oluyemi filed a Form 4 selling 18,197 shares at $34.0285 on 2026-06-22 under a 10b5-1 plan.

Expected impact

Likely minimal near-term impact; any effect would be sentiment-only and quickly absorbed.

Evidence & confidence

The disclosure is a scheduled open-market sale (10b5-1) with no accompanying operational or guidance change stated.

Market effects

Sector

No sector read-across; this is company-specific insider liquidity disclosure.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Even if 10b5-1, repeated insider selling can still be interpreted as reduced confidence by some traders, especially if it coincides with other negative signals not mentioned here.

Key entities

  • issuer
    Hims & Hers Health, Inc.

    Company whose CFO filed the insider sale (Form 4).

  • insider
    Okupe Oluyemi

    Chief Financial Officer who sold shares under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

HIMS insider trading history →

Related articles

SEP 3
$HIMSHighAI 8/10

Hims & Hers Health (NYSE: HIMS) Faces Securities Class Action After FTC Lawsuit Reveal Drives Stock Sharply Lower -- HBSS

Hims & Hers Health (HIMS) faces a securities class action lawsuit following an FTC complaint alleging misconduct, including improper sharing of health data and deceptive billing practices. The FTC's lawsuit caused HIMS shares to drop 14.7% on July 29, 2026, erasing $970M in market cap. The lawsuit claims HIMS misled investors about its business practices and internal controls.

prnewswire.com2 min
SEP 2
$HIMSMed

HIMS Stock Kicks Off September In The Red: FDA’s GLP-1 Alert Steals The Spotlight From Australia Expansion

Hims & Hers Health (HIMS) stock fell 4% to $28.44 on Tuesday after the FDA issued a warning about unapproved GLP-1 weight-loss drugs. The company expanded into Australia but faces profitability pressures due to higher costs of approved GLP-1s. HIMS reported $753M revenue and an $86M net loss in Q2, raising its 2026 revenue forecast to $3.1B-$3.3B.

stocktwits.com2 min
AUG 31
$HIMSMed

Hims & Hers launches weight-loss drugs in Australia

Hims & Hers Health Inc (HIMS) launched GLP-1 weight-loss drugs and other treatments in Australia via its Pilot platform. The company acquired Eucalyptus, an Australian digital health platform, earlier in 2026. Hims aims to expand its services and targets $6.5 billion in revenue by 2030, though international growth has impacted gross margins. According to the company, international business has increased subscriptions and monthly revenue per subscriber by 21% year-over-year.

investing.com2 min
AUG 29
$HIMSMed

Dow, S&P 500, Nasdaq Futures Rise After Trump Says US-Iran War ‘Very Close To Over:’ Why HIMS, MSFT, RUM, NFLX, XNDU Are Trending After-Hours

U.S. stock futures rose after President Trump stated the U.S.-Iran war is 'very close to over.' The S&P 500 and Nasdaq Composite closed at record highs. HIMS surged 24% on FDA news, MSFT gained on AI sentiment, RUM hit a month high, NFLX rose ahead of earnings, and XNDU had its best day. Oil steadied near $91/barrel.

stocktwits.com2 min
AUG 28
$HIMSHighAI 8/10

Hims & Hers (HIMS) CEO Says the FTC Doesn’t Understand His Own Company

Hims & Hers (HIMS) CEO Andrew Dudum defended the company against an FTC lawsuit, citing its revenue growth and subscriber base. Q2 revenue rose 40% YoY to $753M, with a full-year forecast of $3.1B-$3.3B. However, margins fell to 64% from 76%, and free cash flow was negative $68M, raising concerns about profitability and legal risks.

yahoo.com2 min
AUG 28
$INTCHighAI 8/10

Why Are Nasdaq, Dow Futures Trading Mixed Premarket? INTC, SLS, SPCX, RKLB, ASTS, RIOT, FRMI Stocks Are In Focus

U.S. stock futures were mixed on Tuesday, with Nasdaq and Russell 2000 futures up 0.1%, Dow futures down 0.1%, and S&P 500 futures flat. Investors await July CPI data and geopolitical tensions impact sentiment. Key earnings reports include SMCI, CRWV, CAVA, LITE, and SLS. NVDA labeled AI data centers as investable assets, INTC upsized its share sale to $20B, and RIOT secured a $9.1B deal. RKLB shares fell despite a revenue beat, ASTS extended selloff, and SPCX faced lockup expiration pressures.

stocktwits.com3 min